Study: NCT05293249

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dMAb AZD5396
Description: Participants will receive one injection of dMAb AZD5396 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dMAb AZD5396
Description: Participants will receive one injection of dMAb AZD5396 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dMAb AZD5396
Description: Participants will receive one injection of dMAb AZD5396 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dMAb AZD5396
Description: Participants will receive one injection of dMAb AZD5396 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dMAb AZD5396
Description: Participants will receive one injection of dMAb AZD5396 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dMAb AZD5396
Description: Participants will receive one injection of dMAb AZD5396 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dMAb AZD5396
Description: Participants will receive one injection of dMAb AZD5396 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dMAb AZD5396
Description: Participants will receive one injection of dMAb AZD5396 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dMAb AZD8076
Description: Participants will receive one injection of dMAb AZD8076 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dMAb AZD8076
Description: Participants will receive one injection of dMAb AZD8076 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dMAb AZD8076
Description: Participants will receive one injection of dMAb AZD8076 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dMAb AZD8076
Description: Participants will receive one injection of dMAb AZD8076 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dMAb AZD8076
Description: Participants will receive one injection of dMAb AZD8076 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dMAb AZD8076
Description: Participants will receive one injection of dMAb AZD8076 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dMAb AZD8076
Description: Participants will receive one injection of dMAb AZD8076 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dMAb AZD8076
Description: Participants will receive one injection of dMAb AZD8076 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device
Description: The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device
Description: The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device
Description: The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device
Description: The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device
Description: The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device
Description: The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device
Description: The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylenex
Description: Hylenex® recombinant will be used for dMAb AZD5396 and dMAb AZD8076 dose preparation at the clinical site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylenex
Description: Hylenex® recombinant will be used for dMAb AZD5396 and dMAb AZD8076 dose preparation at the clinical site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylenex
Description: Hylenex® recombinant will be used for dMAb AZD5396 and dMAb AZD8076 dose preparation at the clinical site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylenex
Description: Hylenex® recombinant will be used for dMAb AZD5396 and dMAb AZD8076 dose preparation at the clinical site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylenex
Description: Hylenex® recombinant will be used for dMAb AZD5396 and dMAb AZD8076 dose preparation at the clinical site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylenex
Description: Hylenex® recombinant will be used for dMAb AZD5396 and dMAb AZD8076 dose preparation at the clinical site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylenex
Description: Hylenex® recombinant will be used for dMAb AZD5396 and dMAb AZD8076 dose preparation at the clinical site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylenex
Description: Hylenex® recombinant will be used for dMAb AZD5396 and dMAb AZD8076 dose preparation at the clinical site.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device
Description: The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.